← All trials
NCT00915382
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- May 1, 2013
- Completion date
- May 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 625
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of UlsanLead sponsor
- National Cancer Center, KoreaOverall official - principal investigator
- Korea Cancer Center HospitalOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Yeungnam UniversityOverall official - principal investigator
- Gachon UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Seoul Veterans HospitalCollaborator
- National Cancer Center, KoreaCollaborator
- Inje UniversityCollaborator
- Korea Cancer Center HospitalCollaborator
- Sungkyunkwan UniversityCollaborator
- Yeungnam UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Gachon UniversityCollaborator
- University of UlsanReponsible party - principal investigator
- Chonnam National UniversityCollaborator
- Hallym UniversityOverall official - principal investigator
- Hallym UniversityCollaborator
- Kyungpook UniversityOverall official - principal investigator
- Kyungpook UniversityCollaborator
- University of UlsanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.